Phase 4Active, not recruiting
Statin Combined With Amlodipine Treats Primary Aldosteronism (STOP-PA)
A Prospective, Multi-center, Randomized Trial to Compare Statin Combined With CCB to MRA Combined With CCB in Primary Aldosteronism Treatment
- Sponsor
- Third Military Medical University (Academic or other)
- Enrollment
- 180 planned
- Conditions
- Primary Aldosteronism; Statin; Mineralocorticoid Receptor Antagonist; Hypertension
- Interventions
- Simvastatin combined with Amlodipine besylate; Simvastatin combined with Spironolactone and Amlodipine besylate.; Amlodipine besylate combined Spironolactone
- Ages
- adults, older adults
- Registry
- NCT06523465
Full record on ClinicalTrials.gov
From the registry
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Primary outcomes
- changes in plasma aldosterone levels
History
Last registry update
Primary completion
Started
Registered